دانلود کتاب Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, Second Edition

The second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice.  In this new edition, 75% of the “dilemmas” are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn’s disease.  The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking. Each of the 57 evidence-based chapters contains clear learning points, addresses different topics, and provides sound guidance on subjects ranging from optimizing current management through to special management problems and novel treatments. This book is suitable for all medical professionals involved in the care of patients with IBD: established and trainee gastroenterologists, colorectal surgeons, pathologists, radiologists, specialist nurses, pharmacists, dieticians and counselors.Content: Chapter 1 Which will take us Further in IBD—Study of Coding Variation or Epigenetics? (pages 1–6): Miles ParkesChapter 2 IBD in Different Ethnic Groups: Same or Different? (pages 7–11): Rupert W. L. Leong, Dorothy K. L. Chow and Christian P. SelingerChapter 3 How does the Risk ofc Infection Influence Management of IBD around the World? (pages 13–18): Kiran K. Peddi and Ian Craig LawranceChapter 4 Traveling with IBD (pages 19–22): Ing Shian Soon and Gilaad KaplanChapter 5 What to do about Hepatitis B and Hepatitis C in Patients with IBD (pages 23–26): Morven Cunningham and Graham R. FosterChapter 6 CMV in IBD—Passenger or Pathogen? (pages 27–29): Ahmed Kandiel and Bret LashnerChapter 7 Clostridium Difficile in IBD: Impact, Prevention, and Treatment (pages 30–33): Ashwin N. Ananthakrishnan and David G. BinionChapter 8 Prebiotics and Synbiotics: Panacea or Placebo (pages 34–37): James O. LindsayChapter 9 Worms: Light at the End of their Burrow (pages 38–40): John Leung and Joel V. WeinstockChapter 10 Do we Really Need to Vaccinate all Patients with IBD? (pages 41–44): Gauree Gupta and Gil Y. MelmedChapter 11 Biomarkers in IBD: Myth or Marvel? (pages 45–50): Richard B. Gearry and Andrew S. DayChapter 12 Radiation Exposure in IBD: How do we Minimize the Dangers? (pages 51–56): Owen J. O'Connor, Alan N. Desmond, Fergus Shanahan and Michael M. MaherChapter 13 Surveillance Colonoscopy in UC: What is the Best Way to do it? (pages 57–60): Matthew D. RutterChapter 14 New 5?ASAs for Ulcerative Colitis: a Tiny Step or Giant Stride Forward? (pages 61–68): L. Campbell LevyChapter 15 Do 5?ASAs Prevent Cancer? (pages 69–72): Richard Logan and Venkataraman SubramanianChapter 16 Why do we Still Use 5?ASAs in Crohn's Disease? (pages 73–76): Stephen B. Hanauer, Henit Yanai and Emma CalabreseChapter 17 Steroids in Crohn's Disease: Do the Benefits Outweigh the Dangers? (pages 77–82): A. Hillary SteinhartChapter 18 Thioguanine Nucleotide Measurement: Nonadherent, Underdosed, Shunter, or Refractory? (pages 83–88): Miles P. SparrowChapter 19 Thiopurines and the Sun: What should be Done? (pages 89–93): Conal M. Perrett, Jane M. McGregor and Catherine A. HarwoodChapter 20 Do Thiopurines Worsen Risk andc prognosis of Cervical Neoplasia? (pages 94–97): Melissa A. Smith, Jeremy D. Sanderson, Anna Foley and Peter R. GibsonChapter 21 Optimizing Use of Methotrexate (pages 98–101): Anna Foley and Peter R. GibsonChapter 22 Which Calcineurin Inhibitor and When? (pages 102–105): A. Barney HawthorneChapter 23 Are all Anti?TNF Agents the Same? (pages 107–112): Jennifer L. JonesChapter 24 One Drug or Two: Do Patients on Biologics Need Concurrent Immunomodulation? (pages 113–116): Glen A. Doherty and Adam S. CheifetzChapter 25 How do we Identify Patients Needing Early Aggressive Therapy and what Should we Use? (pages 117–119): Marc Ferrante and S?everine VermeireChapter 26 What is the Role of Biologics in UC? (pages 120–123): Joanna K. Law and Brian BresslerChapter 27 What can we do with Crohn's Patients who Fail or Lose Response to Anti?TNF Therapy? (pages 124–128): David T. RubinChapter 28 Which Extraintestinal Manifestations of IBD Respond to Biologics? (pages 129–132): Tina A. Mehta and Chris S. J. ProbertChapter 29 Use and Abuse of Biologics in Pregnancy (pages 133–135): Marla C. DubinskyChapter 30 Is Anti?TNF Therapy Safe to Use in People with a History of Malignancy? (pages 136–139): Mark Lust and Simon TravisChapter 31 The Risks of Immunomodulators and Biologics: What should we Tell Patients? (pages 140–143): Corey A. SiegelChapter 32 When, How, and in whom should we Stop Biologics? (pages 144–147): Edouard Louis, Jacques Belaiche and Catherine ReenaersChapter 33 Avoiding Drug Interactions (pages 149–155): Tim Elliott and Peter M. IrvingChapter 34 Is there Still a Role for Ursodeoxycholic Acid Treatment in Patients with Inflammatory Bowel Disease Associated with Primary Sclerosing Cholangitis? (pages 156–158): Emmanouil Sinakos and Keith D. LindorChapter 35 Stem Cell Transplantation for Crohn's: Will it Fulfill its Promise? (pages 159–163): Venkataraman Subramanian and Christopher J. HawkeyChapter 36 Complementary Therapy: Is there a Needle in the Haystack? (pages 164–167): Shane M. DevlinChapter 37 Optimizing IBD Patients for Surgery and Recovery (pages 169–174): Jonathan M. Wilson and Alastair WindsorChapter 38 Is Surgery the Best Initial Treatment for Limited Ileocecal Crohn's Disease? (pages 175–177): Tom oreslandChapter 39 Laparoscopic or Open Surgery for IBD? (pages 178–181): Donna Appleton and Michael HershmanChapter 40 Optimizing Management of Perianal Crohn's Disease (pages 182–185): David A. Schwartz and Norman R. ClarkChapter 41 Does Anti?TNF Therapy Increase the Risk of Complications of Surgery? (pages 186–191): Ming Valerie Lin, Wojciech Blonski and Gary R. LichtensteinChapter 42 Pouches for Indeterminate Colitis and Crohn's Disease: Act now, Pay Later? (pages 192–195): Phillip FleshnerChapter 43 Dealing with Pouchitis (pages 196–199): Simon D. McLaughlin and Bo ShenChapter 44 Mucosal Healing in IBD: Does it Matter? (pages 201–206): Geert D'HaensChapter 45 Vitamin D in IBD: From Genetics to Bone Health via Cancer and Immunology (pages 207–211): Helen M. Pappa and Richard J. GrandChapter 46 Got Milk? Medication Use and Nursing in Women with IBD (pages 212–214): Sunanda KaneChapter 47 Does Stress Matter? (pages 215–217): Robert G. MaunderChapter 48 IBS is Common in IBD: Fact or Fallacy? (pages 218–221): James Goodhand and David S. RamptonChapter 49 So where is all the Cancer? (pages 222–225): Judith E. Baars and C. Janneke van der WoudeChapter 50 What should Patients with IBD Eat? (pages 227–232): Emile Richman, Keith Leiper and Jonathan M. RhodesChapter 51 Enteral Nutrition in Crohn's—who for, when, how and which Formula? (pages 233–236): Raanan Shamir and Ernest G. SeidmanChapter 52 Optimizing Treatment of Iron Deficiency Anemia (pages 237–240): Hermann Schulze and Axel DignassChapter 53 IBD Standards: Will they Enhance Patient Care? (pages 241–246): Michael D. KappelmanChapter 54 Your Treatment will not Work if the Patient does not take it (pages 247–250): Rob HorneChapter 55 Inflammatory Bowel Disease: What to Tell Your Emergency Department (ED) Team (pages 251–254): Louise LangmeadChapter 56 Transitioning from Pediatric to Adult Care (pages 255–257): Elizabeth J. Hait and Laurie N. FishmanChapter 57 Medicolegal Pitfalls in Inflammatory Bowel Disease Care (pages 258–260): William J. Tremaine